• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Xenon Pharmaceuticals Inc.

    11/14/25 10:29:36 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XENE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    XENON PHARMACEUTICALS INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    98420N105

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    98420N105


    1Names of Reporting Persons

    JANUS HENDERSON GROUP PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,943,885.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,943,885.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,943,885.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    XENON PHARMACEUTICALS INC.
    (b)Address of issuer's principal executive offices:

    3650 GILMORE WAY BURNABY, BC A1 V5G 4W8
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group plc
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    98420N105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    JHIUS may be deemed to be the beneficial owner of 3,912,060 shares
    (b)Percent of class:

    5.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    3912060

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    3912060

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP PLC
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:11/14/2025
    Exhibit Information

    POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

    Get the next $XENE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XENE

    DatePrice TargetRatingAnalyst
    9/3/2025$48.00Overweight
    Wells Fargo
    5/7/2025$55.00Buy
    Chardan Capital Markets
    2/11/2025$67.00Buy
    Deutsche Bank
    10/10/2024$50.00Outperform
    Raymond James
    10/1/2024$53.00Buy
    H.C. Wainwright
    1/4/2024$62.00Buy
    Citigroup
    12/8/2023$63.00Outperform
    Robert W. Baird
    10/24/2023Overweight
    Cantor Fitzgerald
    More analyst ratings

    $XENE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo resumed coverage on Xenon Pharmaceuticals with a new price target

    Wells Fargo resumed coverage of Xenon Pharmaceuticals with a rating of Overweight and set a new price target of $48.00

    9/3/25 8:41:10 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Xenon Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $55.00

    5/7/25 8:39:12 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank initiated coverage on Xenon Pharmaceuticals with a new price target

    Deutsche Bank initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $67.00

    2/11/25 7:18:40 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xenon to Present at Upcoming Investor Conferences

    VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2025 Healthcare ConferenceThursday, November 13, 2025 at 3:20 PM ET Webcast link here Jefferies Global Healthcare Conference in London onWednesday, November 19, 2025 at 11:30 AM GMT/6:30 AM ETWebcast link here Details about company presentations, webcasts, and other events can be found on the Investors section of

    11/6/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Reports Third Quarter 2025 Financial Results & Business Update

    – Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing thera

    11/3/25 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon to Report Q3 2025 Financial Results on November 3, 2025

    VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, November 3, 2025. Conference Call/Webcast Information: Date:Monday, November 3, 2025  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference I

    10/27/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Kelly Thomas Patrick

    4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    10/17/25 6:43:47 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Kelly Thomas Patrick claimed no ownership of stock in the company (SEC Form 3)

    3 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    10/17/25 6:41:56 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO & INTERIM CFO Mortimer Ian exercised 25,000 shares at a strike of $7.69 and sold $1,004,000 worth of shares (25,000 units at $40.16) (SEC Form 4)

    4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

    10/1/25 7:17:11 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Xenon Pharmaceuticals Inc.

    SCHEDULE 13G - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    11/14/25 10:29:36 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Xenon Pharmaceuticals Inc.

    10-Q - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

    11/3/25 4:31:50 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

    11/3/25 4:04:13 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Financials

    Live finance-specific insights

    View All

    Xenon Reports Third Quarter 2025 Financial Results & Business Update

    – Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing thera

    11/3/25 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon to Report Q3 2025 Financial Results on November 3, 2025

    VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, November 3, 2025. Conference Call/Webcast Information: Date:Monday, November 3, 2025  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference I

    10/27/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Reports Second Quarter 2025 Financial Results & Business Update

    – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializ

    8/11/25 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Leadership Updates

    Live Leadership Updates

    View All

    Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

    VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced the appointment of Tucker Kelly as Chief Financial Officer (CFO) and member of the Xenon senior executive team. Mr. Kelly is a proven executive who brings extensive strategic and commercial finance expertise, both in the U.S. and internationally, that will help the Company prepare for the anticipated commercialization of its lead candidate, azetukalner. Azetukalner is currently being studi

    10/16/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

    VANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Darren Cline as Chief Commercial Officer and member of the Xenon senior executive team. In this role, Mr. Cline will lead commercial strategy and operations for the Company's portfolio of product and development candidates, with initial focus on its lead Phase 3 candidate, azetukalner, and first potential launch in epilepsy. Azetukalner is currently being studied in Phase 3 trials for the trea

    6/24/25 8:30:00 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

    – OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner – Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer – Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36 – Patient-reported survey data and literature review illustrate significant mental health and comorbidity burdens of focal onset seizures highlighting areas of unmet need for people living with epilepsy – New pre-clinical data shows Nav1.1 potentiator provides protection against

    12/6/24 4:01:00 PM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XENE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc.

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    11/12/24 10:40:28 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    2/14/24 9:12:03 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

    2/14/24 7:43:11 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care